2 / 41
Notes:
Volume 6, Issue 4 (Suppl)
Clin Pharmacol Biopharm, an open access journal
ISSN: 2167-065X
Page 55
Euro Biopharma & Ethnopharmacology 2017
November 09-11, 2017
&
6
th
International Conference and Exhibition on
November 09-11, 2017 Vienna, Austria
4
th
EUROPEAN BIOPHARMA CONGRESS
PHARMACOLOGY AND ETHNOPHARMACOLOGY
Joint Event
Anti-inflammatory and antileukemia potential of
myrciaria Sp
. ethanol extract
Márcia Goettert
1
,
Shanna Bitencourt
1
, Diorge Marmitt
1
, Stefani Stoll
1
, Bruna Caye
1
, Juliana Dörr
1
, Jarbas Oliveira
2
and
Stefan Laufer
3
1
Univates, Lajeado, Brazil
2
Pontifical Catholic University of Rio Grande do Sul, Brazil
3
University of Tübingen, Germany
M
ost anti-inflammatory and anticancer drugs produced are derived from naturally occurring compounds or their derivatives.
There is a constant search for new metabolites from natural origin, particularly from plants, which have potential for efficacious
drugs. Myrtaceae, a plant family present in tropical areas, is one of the most studied on biological activities.
Myrciaria
genus belongs
to this family and comprises several species; however, few studies have shown their therapeutic potential. The present study aimed
to investigate the anti- inflammatory potential and cytotoxicity of the ethanol extract of a species of the
Myrciaria
genus on RAW
267.4 macrophage cells, human peripheral blood mononuclear cells (PBMCs) and Jurkat acute T-lymphocytic leukemia cells. First,
RAW 267.4 and PBMCs were treated with increasing concentrations of the extract to assess cytotoxicity for 48 h and 96 h using
Alamar blue and Trypan blue exclusion, respectively. In addition, lymphoproliferation was assayed on phytohemagglutinin (PHA)-
stimulated PBMCs using MTT method. TNF-α levels were determined by ELISA after RAW 267.4 and PBMCs were pre-incubated
with the extract and then challenged with LPS. Protein expression of inflammation-associated markers (NF-kB, p38α and p-p38)
in LPS-activated RAW 264.7 cells was assessed by Western blot. In addition, the extract was screened for p38 MAPK inhibition
using cell-free enzyme activity assay. Later, Jurkat cells were challenged for 24 h with the extract and cytotoxicity was determined
by Trypan blue exclusion. After challenging RAW 264.7 and PBMCs with
Myrciaria
sp. extract, a slight decrease (p<0.05) on RAW
264.7 viability was observed with the maximum concentration tested (200 μg/mL), while PBMCs were not affected by the extract.
However, PHA-stimulated PBMCs had a decreased proliferation when cultured with 200 µg/mL extract. In addition, when both LPS-
activated cells were pre- treated with the extract, there were dose-dependent decrease in TNF-α levels (p<0.001), suggesting possible
immunomodulatory and anti-inflammatory activities of the extract. Furthermore, Western blotting on RAW 264.7 cells showed that
the extract was capable to inhibit LPS-induced NF-kB activation and p38 phosphorylation. Besides,
Myrciaria
sp. extract presented
a great p38 inhibitory activity. On Jurkat cells, the ethanol extract showed cytotoxicity after 24 h, indicating a selectivity. The IC50 of
the extract was 127.7 µg/mL. The results suggest that
Myrciaria
sp. ethanol extract present great biological and is a potent inhibitor
of p38 MAPK suggesting an action mechanism with selective activity that can be used in the development of anti-inflammatory and
antileukemic drugs or phytomedicines.
marciagoettert@gmail.comMarcia Goettert et al., Clin Pharmacol Biopharm 2017, 6:4(Suppl)
DOI: 10.4172/2167-065X-C1-026